Basic Information
| LncRNA/CircRNA Name | AFAP1-AS1 |
| Synonyms | AFAP1-AS1, AFAP1-AS, AFAP1AS, LOC84740 |
| Region | GRCh38_4:7754090-7778928 |
| Ensemble | ENSG00000272620 |
| Refseq | NR_026892 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot |
| Sample | lung cancer tissues, cell lines (A549, H1299 ,H460) |
| Expression Pattern | up-regulated |
| Function Description | In the current study, we found that AFAP1-AS1 was substantially over expressed in lung cancer tissues and cell lines. In addition, AFAP1-AS1 expression level was proven to be associated with the malignant features of lung cancer. Knockdown of AFAP1-AS1 significantly suppressed cell proliferation by increasing cell apoptosis and G0/G1 phase retardation of cell cycle in lung cancer cells. Furthermore, AFAP1-AS1 knockdown could suppress tumor growth of lung cancer in BALB/c nude mice. We also identified that AFAP1-AS1 silencing could influence the expression of AFAP1 and KRT1 on mRNA and protein level by cis and trans regulatory mechanism. Moreover, the oncogenic activities of AFAP1-AS1 on cell proliferation are partially mediated by KRT1.With only 10-15 % of 5-year overall survival, lung cancer accounts for more than one quarter of all cancer deaths. The most important factor for survival of lung cancer patients is the stage of the disease at diagnosis. |
| Pubmed ID | 29212176 |
| Year | 2017 |
| Title | Silencing of lncRNA AFAP1-AS1 suppressed lung cancer development by regulatory mechanism in cis and trans. |
External Links
| Links for AFAP1-AS1 | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |